Healthcare / Diagnostics & ResearchNasdaqGM
$10.85
-0.41 (-3.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-67.2M · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.1%
↓Gross Margin
22.7%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+28.5%
FCF CAGR
—
FCF margin
-114.1%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.6M · net income $-81.3M · FCF $-79.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $69.6M | $69.6M | $84.6M | $73.5M | $65.0M | $85.5M | $78.6M | $65.2M | $37.8M | $9.4M |
| Net Income | $-81.3M | $-81.3M | $-81.3M | $-108.3M | $-113.3M | $-65.2M | $-41.3M | $-25.1M | $-19.9M | $-23.6M |
| EBITDA | $-71.0M | $-71.0M | $-70.3M | $-96.8M | $-104.6M | $-59.3M | $-36.4M | $-17.7M | $-10.7M | $-20.9M |
| EPS | — | — | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | — | — | — |
| Gross Margin | 22.7% | 22.7% | 31.7% | 24.8% | 20.5% | — | — | — | — | — |
| Operating Margin | -126.4% | -126.4% | -80.7% | -131.0% | -177.6% | -76.4% | -53.6% | -34.4% | -36.5% | -236.0% |
| Net Margin | -116.7% | -116.7% | -96.1% | -147.4% | -174.2% | -76.3% | -52.5% | -38.5% | -52.6% | -251.2% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.15 | 0.15 | 0.22 | 0.37 | 0.22 | — | — | — | — | — |
| Current Ratio | 6.61 | 6.61 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-79.5M | $-79.5M | $-46.8M | $-67.2M | $-120.1M | $-81.9M | $-45.9M | $-26.5M | $-2.3M | $-4.9M |
| Returns | ||||||||||
| ROE | -31.1% | -31.1% | -40.0% | -83.7% | -51.9% | -21.0% | -21.2% | -23.5% | 18.7% | 25.5% |
| Valuation | ||||||||||
| P/B | 4.26 | 4.26 | 1.94 | 0.80 | 0.48 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | -17.7% | -17.7% | 15.2% | 13.0% | — | 8.7% | 20.6% | 72.6% | 302.2% | — |
| EPS Growth | — | — | 39.1% | 9.3% | — | -24.2% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+124.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.37 → n/d
Residual
+124.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.